Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods
Authors:
- Julian NamJNJulian Nam
- Andrew BriggsABAndrew Briggs
- Jamie LaylandJLJamie Layland
- Keith G. OldroydKOKeith G. Oldroyd
- Nick CurzenNCNick Curzen
- Arvind SoodASArvind Sood
- Kanarath BalachandranKBKanarath Balachandran
- Raj DasRDRaj Das
- Shahid JunejoSJShahid Junejo
- Hany EteibaHEHany Eteiba
- Mark C. PetrieMPMark C. Petrie
- Mitchell LindsayMLMitchell Lindsay
Open Access
- 14 November 2015
- journal article
- research article
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 13 (1) , 1-9
Abstract
In the Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST elevation myocardial infarction (FAMOUS) clinical trial, FFR was shown to significantly reduce coronary revascularisation, compared to visual interpretation of standard coronary angiography without FFR. We estimated the cost-effectiveness from a UK National Health Service perspective, based on the results of FAMOUS. A mixed trial- and model-based approach using decision and statistical modelling was used. Within-trial (1-year) costs and QALYs were assembled at the individual level and then modelled on subsequent management strategy [coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or medical therapy (MT)] and major adverse coronary events (death, MI, stroke and revascularisation). One-year resource uses included: material, hospitalisation, medical, health professional service use and events. Utilities were derived from individual EQ5D responses. Unit costs were derived from the literature. Outcomes were extended to a lifetime on the basis of MACE during the 1st year. Costs and QALYs were modelled using generalized linear models whilst MACE was modelled using logistic regression. The analysis adopted a payer perspective. Costs and outcomes were discounted at 3.5 %. Costs were related to the subsequent management strategy and MACE whilst QALYs were not. FFR led to a modest cost increase, albeit an imprecise increase, over both the trial [£112 (−£129 to £357)] and lifetime horizons [£133 (−£199 to £499)]. FFR led to a small, albeit imprecise, increase in QALYs over both the trial [0.02 (−0.03 to 0.06)] and lifetime horizons [0.03 (−0.21 to 0.28)]. The mean ICER was £7516/QALY and £4290/QALY over the trial and lifetime horizons, respectively. Decision remained high; FFR had 64 and 59 % probability of cost-effectiveness over trial and lifetime horizons, respectively. FFR was cost-effective at the mean, albeit with considerable decision uncertainty. Uncertainty can be reduced with more information on long-term health events.Keywords
Funding Information
- British Heart Foundation (GB) (PG/11/55/28999)
This publication has 28 references indexed in Scilit:
- Assessing the value of diagnostic tests: a framework for designing and evaluating trialsBMJ, 2012
- Fractional Flow Reserve in Unstable Angina and Non–ST-Segment Elevation Myocardial InfarctionJACC: Cardiovascular Interventions, 2011
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal, 2010
- Grading quality of evidence and strength of recommendations for diagnostic tests and strategiesBMJ, 2008
- Percutaneous Coronary Intervention of Functionally Nonsignificant StenosisJACC, 2007
- Comparative accuracy: assessing new tests against existing diagnostic pathwaysBMJ, 2006
- Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?International Journal of Cardiology, 2005
- Percutaneous coronary intervention or bypass surgery in multivessel disease? A tailored approach based on coronary pressure measurementCatheterization and Cardiovascular Interventions, 2004
- Does Visual Interpretation of the Coronary Arteriogram Predict the Physiologic Importance of a Coronary Stenosis?New England Journal of Medicine, 1984